---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-007944"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2023-02-22T23:59:59+00:00"
generated_at: "2026-06-19T06:01:39.489859+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ionis reports FY2022 revenue $587M, net loss $270M; eplontersen NDA submitted; 2023 guidance revenue >$575M

## Summary
- FY2022 total revenue $587M (down from $810M in 2021); net loss $270M vs $29M loss in 2021.
- Q4 2022 revenue $152M, net loss $52M; non-GAAP net loss $168M.
- Eplontersen NDA submitted to FDA for ATTRv-PN; tofersen under FDA/EMA review; olezarsen Fast Track for FCS.
- 2023 guidance: revenue >$575M, non-GAAP operating expenses ~$970-995M, net operating loss <$425M.
- Cash, cash equivalents and short-term investments $2.0B at Dec 31, 2022; plus $500M from Royalty Pharma in Jan 2023.

## SEC filing metadata
- accession: 0001140361-23-007944
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2023-02-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036123007944/0001140361-23-007944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036123007944/brhc10048570_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-007944
- JSON: https://secwatch.observer/filing/0001140361-23-007944.json
- Plain text: https://secwatch.observer/filing/0001140361-23-007944.txt

## Key facts
- Earnings Releases
  IONIS PHARMACEUTICALS INC reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On February 22, 2023, Ionis Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the Company’s financial results for the quarter and fiscal year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/874015/000114036123007944/0001140361-23-007944-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.